Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 7, 2005, Pages 1202-1207

  Sawada, Kaori ^a   Noda, Keisuke ^a   Nakajima, Hiroto ^a   Shimbara, Naoki ^a   Furuichi, Yasuhiro ^a   Sugimoto, Masanobu ^a  

^a GeneCare Research Institute   (Japan)

Author keywords

Anticancer agent; Assessment; DNA modifying agent; Immortalized cell line; Screening

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; COLCHICINE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; PACLITAXEL; TIOGUANINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NONHUMAN;

ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS;

EID: 24944447099     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.1202     Document Type: Article

References (24)

1. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R., Cancer Res., 48, 589-601 (1988).
2. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Cambell H., Nayo J., Boyd M., J. Natl. Cancer Inst., 83, 757-766 (1991).
3. Vassilev L. T., Kazmer S., Marks I. M., Pezzoni G., Sala F., Mischke S. G., Foley L., Berthel S. J., Anticancer Drug Des., 16, 7-17 (2001).
4. Miller G., Fields B. N., Knipe K. M. (eds.), "Virology," Raven Press, New York, 1990, pp. 1921-1958.
5. Nilsson K., "The Nature of Lymphoid Cell Lines and Their Relationship to the Virus," Springer-Verlag, New York, 1979.
6. Nilsson K., Hum. Cell, 5, 25-41 (1992).
7. Counter C. M., Avilion A. A., LeFeuvre C. E., Stewart N. G., Greider C. W., Harley D. B., Bacchetti S., EMBO J., 11, 1921-1929 (1992).
8. Counter C. M., Botelho F. M., Wang P., Harley C. B., Bacchetti S., J. Virol., 68, 3410-3414 (1994).
9. Sugimoto M., Ide T., Goto M., Furuichi Y., Mech. Ageing Dev., 107, 51-60 (1999).
10. Sugimoto M., Ide T., Goto M., Furuichi Y., J. Virology, 73, 9690-9691 (1999).
11. Sugimoto M., Tahara H., Ide T., Furuichi Y., Cancer Res., 64, 3361-3364 (2004).
12. Tahara H., Tokutake Y., Maeda S., Kataoka H., Watanabe T., Satoh M., Matsumoto T., Sugawara M., Ide T., Goto M., Furuichi Y., Sugimoto M., Oncogene, 15, 1911-1920 (1997).
13. Okubo M., Tsurukubo Y., Higaki T., Kawabe T., Goto M., Murase T., Ide T., Furuichi Y., Sugimoto M., Cancer Genet. Cytogenet., 129, 30-34 (2001).
14. Sugimoto M., Tahara H., Okubo M., Kobayashi T., Goto M., Ide T., Furuichi Y., Cancer Genet. Cytogenet., 152, 95-100 (2004).
15. Okada M., Goto M., Furuichi Y., Sugimoto M., Biol. Pharm. Bull., 21, 235-239 (1998).
16. Takahashi T., Kawabe T., Okazaki Y., Itoh C., Noda K., Tajima M., Satoh M., Goto M., Mitsui Y., Tahara H., Ide T., Furuichi Y., Sugimoto M., DNA Cell Biol., 22, 727-735 (2003).
17. Satoh M., Yasuda T., Higaki T., Goto M., Tanuma S., Ide T., Furuichi Y., Sugimoto M., Cell Struct. Funct., 28, 61-70 (2003).
18. Kataoka H., Tahara H., Watanabe T., Sugawara M., Ide T., Goto M., Furuichi Y., Sugimoto M., Differentiation, 62, 203-211 (1997).
19. Lonn U., Lonn S., Nylen U., Winblad G., Cancer Res., 49, 1085-1089 (1989).
20. Warren D. J., Slordal L., Anal. Biochem., 215, 278-283 (1993).
21. Skeel R. T., "Handbook of Cancer Chemotherapy," Fifth ed., Lippincott Williams & Wilkins, New York, 1999.
22. Shiratori M., Sakamoto S., Suzuki N., Tokutake Y., Kawabe Y., Enomoto T., Sugimoto M., Goto M., Matsumoto T., Furuichi Y., J. Cell Biol., 144, 1-9 (1999).
23. Lebel M., Leder P., Proc. Natl. Acad. Sci. U.S.A., 95, 13097-13102 (1998).
24. Rooney C. M., Smith C. A., Ng C. Y., Loftin S., Li C., Krance R. A., Brenner M. K., Heslop H. E., Lancet, 345, 9-13 (1995).